SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to a report of security flaws in a battlefield communications system, leading to a sharp intraday drop. While some investors are concerned about the implications of these vulnerabilities, others view the dip as a buying opportunity, citing the company's response that the issues have been addressed and the prototype nature of the system.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a mix of excitement and skepticism around its recent surge, with community members debating whether it's a legitimate rise or a potential bubble. The stock's connection to the quantum computing sector and AI, coupled with discussions about its valuation and revenue, are fueling the conversations. Some traders are pointing to potential short squeezes, while others are wary of a significant pullback.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid high trading volume and community excitement, with some investors anticipating significant catalysts in the near future, possibly driven by speculation around new partnerships. Community members are pointing to the high short interest, hinting at a potential squeeze, while also highlighting the company's potential for growth in the eVTOL sector.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

LKNCY is trending as investors celebrate the stock finally breaking the $40 mark, a level many have been watching for a long time, driven by expansion news. The community is expressing bullish sentiment, anticipating further growth and a potential Nasdaq relisting. Overall, the mood is optimistic as traders reflect on the company's journey and future potential.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors debate the implications of its AI spending and recent moves into private debt markets, drawing comparisons to pre-2008 financial tactics. Community discussion revolves around the stock's volatility and whether its pullback represents a buying opportunity or reflects deeper concerns about AI investments. Some are pointing to potential data center deals as a possible catalyst.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience ($ANRO) is trending as investors react to news of $IMG pulling its S-1 filing, eliminating concerns about potential dilution. The community is also buzzing about ANRO's expansion into crypto AI, including a $55M Bitcoin deal and a $20M fund with iZUMi. Bullish sentiment seems to be building amidst discussions of potential breakouts and short squeezes.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

SCLX is trending due to a sharp decline in its stock price, sparking community concern and speculation about the reasons behind it, including the potential impact of the DVLT deal and the company's leadership. Some investors are questioning the company's direction, while others are anticipating a potential short squeeze or positive news to reverse the current trend. Discussions also involve the possibility of a strategic play related to Semnur and its valuation.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble ($RUM) is trending due to its strategic partnership with Perplexity AI, sparking discussions about enhanced content discovery and potential synergies within the AI space. The community is actively debating the impact of this partnership, especially given Rumble's existing ties to crypto through Tether and its potential to become a major cloud provider. High short interest is adding fuel to the fire, with many anticipating a significant short squeeze.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics ($RR) is trending with significant volume, fueled by community excitement and talk of a potential surge to new highs. Investors are actively discussing the company's potential to reach mid-cap status and the anticipation of news in October, while some reference a past short report as a catalyst for the stock's recent momentum. Discussion also includes comparisons to other robotics companies and speculation around the impact of robotics on the future.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

TDOC is trending as community members discuss its potential for a short squeeze, citing high short interest and upcoming catalysts. Bullish sentiment is fueled by mentions of technical indicators, such as breaking above key moving averages, and speculation around potential AI integration and partnerships. Some investors express frustration with the stock's historical performance and management, while others remain optimistic about its long-term growth potential in the telehealth sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hims & Hers Expands Health Access Through Subscription Revenue Model

HIMS boosts predictable revenue and customer loyalty with a flexible, subscription-based model across key health categories.

OMCL or HIMS: Which Is the Better Value Stock Right Now?

OMCL vs. HIMS: Which Stock Is the Better Value Option?

Eli Lilly's stock jumped over 5% on Tuesday after U.S.President Donald Trump unveiled a plan to lower U.S. drug prices, which included a “TrumpRx” direct-to-consumer website and a pricing agreement with Pfizer.&nbsp;Pfizer became the first company to accept the administration’s terms, agreeing to slash drug prices by up to 85% and secure a three-year exemption from pharmaceutical tariffs.BMO Capital Markets analyst Evan Seigerman said the Pfizer deal effectively provided a model for other drugmakers such as Eli Lilly to balance pricing cooperation with policy compliance. He said the structure gave the administration a political win while avoiding the need for harsher price controls or new tariffs, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-30/pfizer-to-cut-medicaid-drug-prices-in-deal-with-trump-wapo">report</a>.Cantor analyst Carter Gould said the sharp rally in pharmaceutical shares reflected investor relief that the policy measures were more symbolic than financially disruptive. He noted that Pfizer’s announcement did not change any earnings guidance, suggesting that the market viewed the move as a sign of easing regulatory uncertainty rather than a fundamental earnings risk.The S&amp;P 500 Pharmaceuticals Index rose nearly 4%, while Lilly recorded its best day in more than a month. Pfizer climbed nearly 7%, marking its strongest single-day gain in almost four years.Raymond James health policy analyst Chris Meekins said the TrumpRx program was unlikely to materially affect consumers’ costs unless insurance reforms followed. He said that if the administration’s pricing actions stopped at this stage, it would amount to a win for the pharmaceutical industry, CNN&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edition.cnn.com/2025/09/30/politics/pfizer-drug-prices-trump">noted</a>.Meanwhile, Futurum Equities chief market strategist Shay Baloor&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/StockSavvyShay/status/1973057650150764638">wrote on X</a> that Trump’s agreement with Pfizer to launch TrumpRx, which allows consumers to buy discounted medications directly from manufacturers, could hurt insurers and pharmacy benefit managers.&nbsp;Baloor viewed companies such as Eli Lilly, UnitedHealth, Cigna, and Walgreens as potential losers from the shift, while naming Hims &amp; Hers Health among the likely beneficiaries.Eli Lilly stated that it was in active discussions with the administration to expand patient access, signaling its readiness to participate in broader efforts to increase affordability. The statement followed Trump’s call for drugmakers to align U.S. prices with international levels under his “Most Favored Nation” directive.Commerce Secretary Howard Lutnick said negotiations with major drugmakers were ongoing, while Trump described the plan as a step toward ending what he called global price disparities in medicine.Eli Lilly has not disclosed details of its discussions but said it remains focused on expanding access and improving affordability for patients in the U.S..On Stocktwits, retail sentiment was ‘bullish’ for Eli Lilly and ‘extremely bullish’ for Pfizer, with 24-hour message volumes surging 191% and 780%, respectively.<figure class="image"><img style="aspect-ratio:618/55;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_10_14_21_PM_png_d8474c8869.webp" alt="Screenshot 2025-09-30 at 10.14.21 PM.png" width="618" height="55"><figcaption>LLY sentiment and message volume as of 10:15 p.m. ET, Sept. 30 | source: Stocktwits</figcaption></figure>One user noted that the new TrumpRx model, which eliminates middlemen, is unlikely to impact margins for companies such as Eli Lilly, Merck, and Pfizer, describing it as a direct-to-consumer shift.&nbsp;<stembedurl>https://stocktwits.com/Jessdog77/message/630503208</stembedurl>Another user described Eli Lilly as a strong performer that continues to show unstoppable momentum.<stembedurl>https://stocktwits.com/Stonkapedia/message/630566985</stembedurl><a href="https://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> has declined 0.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/nike-retail-investors-turn-more-bullish-as-q1-performance-confirms-turnaround-progress-good-report-in-difficult-market/chCooXAR39N">Nike Retail Investors Turn More Bullish As Q1 Performance Confirms Turnaround Progress: 'Good Report In Difficult Market'</a>

The entrance to the Eli Lilly factory in Kinsale, Co Cork, where weight loss drug Mounjaro is made. Picture date: Sunday May 18, 2025.

Eli Lilly Stock Jumps As Trump’s Drug Price Crackdown Spurs Sector Rally; Analysts Say Pfizer Deal Sets Template For Big Pharma

Analysts said the plan signals a political win that could reshape how major drugmakers engage with U.S. policymakers.

Equity

Analysts said the plan signals a political win that could reshape how major drugmakers engage with U.S. policymakers.


Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why

The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $59.12, representing a +1.23% change from its previous close.

HIMS vs. DOCS: Which Digital Health Platform Is a Better Investment?

Hims & Hers and Doximity are transforming digital health, but which leads in earnings growth and platform expansion? Let's see.

Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $56, signifying a -2.95% move from its prior day's close.

Hims & Hers Expands Care Ecosystem via Global and Digital Innovation

HIMS is scaling globally with AI-powered care, new treatments and an $870 million boost to expand its digital ecosystem.

U.S. equities declined in Tuesday’s midday trade, with the crucial two-day Federal Open Market Committee (FOMC) meeting currently underway.Ahead of the release of the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fed-meeting-date-fomc-rate-decision-when-announce-what-to-expect/chwynHURdzn">Fed meeting's outcome</a>, President Donald Trump&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-fed-should-be-independent-should-listen-to-smart-people-like-me/chwylmVRdzX">called on</a> the central bank to listen to “smart people” like himself, while stating that the central bank should remain independent.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.16% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq, fell 0.11%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, declined 0.26%.Here are the top stocks making the biggest moves in Tuesday’s midday trade:<a href="https://stocktwits.com/symbol/BBAI">BigBear.ai Holdings Inc. (BBAI)</a>BigBear.ai shares were up more than 15% in Tuesday’s midday trade after a recent&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bigbear-sparks-retail-buzz-as-congressional-disclosure-fuels-federal-win-rumor/chwy743RdyX">disclosure</a> by Representative Lisa McClain (R-Mich.) regarding the purchase of BBAI stock worth between $15,000 and $50,000 as part of a 401K account held with Charles Schwab. BigBear.ai was the top trending stock on Stocktwits at the time of writing.<a href="https://stocktwits.com/symbol/BBAI">BBAI stock</a> is up 32% year-to-date.<a href="https://stocktwits.com/symbol/TSLA">Tesla Inc. (TSLA)</a>Tesla shares continued to rise, gaining nearly 3% in Tuesday’s midday session following a surge on Monday after co-founder and CEO Elon Musk&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-shares-surge-elon-musk-purchases-stock-first-time-since-2020/chwwIvpRdUG">acquired</a> 2.57 million shares of the company on Friday, at an aggregate value of nearly $1 billion.<a href="https://stocktwits.com/symbol/TSLA">TSLA stock</a> is up 4% year-to-date.<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers Health Inc. (HIMS)</a>Hims &amp; Hers Health shares dropped by over 7% in Tuesday’s midday trade after the U.S. Food and Drug Administration (FDA)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-tumbles-7-percent-after-fda-letter/chwyNFWRdzV">sent</a> a letter alleging that the company’s claims concerning compounded Semaglutide products, used for weight loss, are “false or misleading.”<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is up 109% year-to-date.<a href="https://stocktwits.com/symbol/RKLB">Rocket Lab Corp. (RKLB)</a>Rocket Lab shares dropped over 12% in Tuesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rocket-lab-stock-tumbles-10-percent-today-here-is-what-happened/chwyZ66Rdzl">announced</a> a $750 million at-the-market (ATM) equity offering.<a href="https://stocktwits.com/symbol/RKLB">RKLB stock</a> is up 87% year-to-date.<a href="https://stocktwits.com/symbol/WBD">Warner Bros. Discovery Inc. (WBD)</a>Warner Bros. Discovery shares fell over 8% in Tuesday’s midday trade after analysts at TD Cowen downgraded the stock to ‘Hold’ from ‘Buy’ on concerns that “there would be a lot of hurdles” in Paramount Skydance Corp.’s (PSKY)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-reportedly-plans-majority-cash-bid-for-warner-bros-discovery/chwNp8zRdvx">reported</a> bid to acquire the former, according to TheFly. Senator Elizabeth Warren on Tuesday also voiced her disapproval, calling to block the deal, and said in a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/ewarren/status/1967936711264272677">post</a> on X that it “would be a dangerous concentration of power over our media and news.”<a href="https://stocktwits.com/symbol/WBD">WBD stock</a> is up 69% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fed-meeting-date-fomc-rate-decision-when-announce-what-to-expect/chwynHURdzn">Fed Meeting Date: Here's When FOMC's Rate Decision Will Be Announced, And What You Should Expect</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

BigBear.ai, Tesla, Hims & Hers, Rocket Lab, Warner Bros Discovery: Stocks Making The Biggest Moves Today

BigBear.ai shares were up more than 15% on Tuesday after a recent disclosure by Representative Lisa McClain regarding the purchase of BBAI stock worth between $15,000 and $50,000.

Shares of Hims &amp; Hers Health (HIMS) slumped 7% on Tuesday after the U.S. Food and Drug Administration (FDA) sent a letter to the company CEO regarding the sale of compounded drug products.In the letter <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hers-09092025">dated</a> September 9, the agency alleged that the company’s claims concerning compounded Semaglutide products, used for weight loss, are “false or misleading.” The FDA also noted that this is a violation of certain sections of the Federal Food, Drug, and Cosmetic Act.The FDA pointed out that compounded drug products are not approved by it. “Your claims imply that your products are the same as an FDA-approved product when they are not,” the letter said, while urging the company to take immediate action to address violations. A failure to adequately address any violation may result in legal action without further notice, it added.The FDA further alleged that these compounded products are misbranded and noted that the introduction of misbranded products into interstate commerce is prohibited. While the letter referred to two claims made on compounded Semaglutide products made on Hims’ website, it does not represent an exhaustive list of misbranding violations, the agency said.The FDA has given CEO Andrew Dudum 15 working days from the receipt of the letter to provide a written response describing the steps taken to address violations or to provide reasoning and supporting information if he believes the company is not in violation.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> jumped from ‘bullish’ to 'extremely bullish' territory over the past 24 hours, while message volume stayed at ‘high’ levels.In June, Novo Nordisk (NVO) <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-plunges-after-novo-nordisk-ends-wegovy-partnership/chm55y3RR5v">said</a> that it is halting collaboration with Hims &amp; Hers for the sale of its blockbuster weight loss drug Wegovy, the key ingredient of which is Semaglutide. Novo said that Hims &amp; Hers failed to adhere to the law, which prohibits mass sales of compounded drugs. It further alleged that the telehealth operator is promoting and selling illegitimate, knockoff versions of Wegovy and has hence decided to halt the collaboration entered into in late April.Dudum, however, subsequently <a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-hits-back-at-novo-nordisk-after-collaboration-end/chm5fs2RRd4">alleged</a> that Novo’s management is “misleading the public.” The CEO stated in a post on X that the pharmaceutical company’s commercial team has been pressuring the company to control clinical standards and steer patients toward Wegovy, regardless of whether it is clinically the best option for patients.HIMS stock has more than doubled its value this year and tripled over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-to-set-up-5-billion-facility-in-virginia/chwymFcRdzj">Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen on May 04, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Hims & Hers Stock Draws Investor Attention After Tumbling 7% – Here’s What Happened

In a letter dated September 9, the FDA alleged that the company’s claims concerning compounded Semaglutide products are “false or misleading.”

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HIMS News

HIMS Hims & Hers Health Inc